Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Liabilities and Shareholders Equity: 2024-2025

Historic Liabilities and Shareholders Equity for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $649.4 million.

  • Kura Oncology's Liabilities and Shareholders Equity rose 35.62% to $649.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year change of. This contributed to the annual value of $760.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Kura Oncology reported Liabilities and Shareholders Equity of $649.4 million as of Q3 2025, which was down 4.84% from $682.4 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Liabilities and Shareholders Equity peaked at $760.2 million during Q4 2024, and registered a low of $478.8 million during Q3 2024.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $649.4 million (2025), whereas its average is $626.2 million.
  • Data for Kura Oncology's Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 35.62% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Liabilities and Shareholders Equity stood at $760.2 million in 2024, then soared by 35.62% to $649.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $649.4 million for Q3 2025, versus $682.4 million for Q2 2025 and $743.8 million for Q1 2025.